[144] UNITED THERAPEUTICS Corp SEC Filing
Paul Mahon submitted a Form 144 notice reporting proposed sales of Common Stock, consisting of repeated blocks of 8,300 shares tied to stock option exercises.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Paul Mahon submitted a Form 144 notice reporting proposed sales of Common Stock, consisting of repeated blocks of 8,300 shares tied to stock option exercises. The filing lists multiple sale dates in Q1–Q2 2026 (examples: 02/05/2026, 03/05/2026, 04/02/2026, 04/16/2026).
The transactions are described as Stock Option Exercise and appear filed through Morgan Stanley Smith Barney LLC as broker. The filing is a regulatory notice of proposed resale activity, not a company operational disclosure.
Insights
Routine insider resale notices showing option-based dispositions.
The filing lists multiple proposed sales of 8,300 shares tied to option exercises on several dates in 2026, reported through a broker-dealer. Form 144 is a regulatory notice required for resale by affiliates and does not itself confirm execution.
Impact is procedural: subsequent confirmatory Form 4s or broker reports would show final execution and cash flow. Timing and scale do not alone indicate material change to company fundamentals.
AI-generated analysis. How Rhea-AI works. Not financial advice.